News Sentiment

HCM sentiment intelligence

HUTCHMED DRC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 66 Constructive news tone 36 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 11.07 Week of 10 Jul 2026
Weighted tone 66/100

Constructive news tone

Market reaction Positive news being faded

Constructive headlines are not being rewarded by price, which raises a rejection flag.

Primary event Market update

74/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-3.2% over one week, +1.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors

Market Reaction

Positive news being faded

75/100 confidence

Constructive headlines are not being rewarded by price, which raises a rejection flag.

Primary event Market update 74/100 classification
One-week reaction -3.2% Price reacting lower
Trend fit Trend inactive 1.0% over four weeks
Fair value -30.0% Below fair value
Sentiment-trend disagreement Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 16
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 6
TradingView 4
Market source 3
GlobeNewswire 3
Moomoo 2
Investing.com Canada 2
London South East 2
grafa.com 2

Event Lens

What the news is about

Classified themes
Market update 14
Regulatory and legal 12
Earnings 7
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 36
GuruFocus Direct company coverage

HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors

HUTCHMED (China) Ltd (HCM) shares surged 3.0% to $11.60 on July 15, 2026. The company is considered modestly undervalued with a GF Value™ of $13.72, and its GF Score™ of 79/100 indicates above-average performance with strong growth and valuation, despite lower profitability. No i

Tone
Positive 71/100
Event
Market update
Published
16 Jul 2026 00:10
Source
GuruFocus
Market source Direct company coverage

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

HUTCHMED (China) Limited announced that its drug ORPATHYS® (savolitinib) received conditional approval from China's National Medical Products Administration (NMPA) for treating advanced gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who

Tone
Positive 88/100
Event
Regulatory and legal
Published
03 Jul 2026 04:10
Source
Market source
Investing.com Canada Direct company coverage

HUTCHMED stock surges on China gastric cancer drug approval By Investing.com

HUTCHMED shares surged by 6.5% following the conditional approval of its drug ORPATHYS® (savolitinib) in China for advanced gastric cancer or gastroesophageal junction adenocarcinoma. This marks the first selective MET inhibitor approved for this patient population in China, targ

Tone
Positive 93/100
Event
Regulatory and legal
Published
03 Jul 2026 03:09
Source
Investing.com Canada
London South East Direct company coverage

Hutchmed drug approved in China for advanced gastric cancer

Hutchmed China Ltd has received conditional approval from China's NMPA for its drug savolitinib ('ORPATHYS') to treat advanced gastric cancer patients with MET amplification, a condition with poor prognosis. This marks the drug's third approved indication in China and is a joint

Tone
Positive 92/100
Event
Regulatory and legal
Published
02 Jul 2026 13:25
Source
London South East
grafa.com Direct company coverage

HUTCHMED wins China approval for ORPATHYS cancer drug

HUTCHMED (NASDAQ:HCM) has received conditional approval from China's National Medical Products Administration for its cancer drug ORPATHYS (savolitinib). This approval is for the treatment of MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma in patients w

Tone
Positive 82/100
Event
Regulatory and legal
Published
02 Jul 2026 12:40
Source
grafa.com
UK Investor Magazine Direct company coverage

AIM movers: Hutchmed granted new drug application in China and ex-dividends

Hutchmed (China) Ltd saw its share price jump after receiving conditional approval for its new drug ORPATHYS in China. Other companies like James Cropper, Zephyr Energy, James Latham, Sintana Energy, and Huddled Group also experienced share price increases due to positive develop

Tone
Positive 73/100
Event
Regulatory and legal
Published
02 Jul 2026 10:40
Source
UK Investor Magazine
Stock Titan Direct company coverage

NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer

HUTCHMED (HCM) has received conditional approval from China's National Medical Products Administration (NMPA) for its drug ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with MET amplification, after at least two

Tone
Positive 73/100
Event
Regulatory and legal
Published
02 Jul 2026 09:40
Source
Stock Titan
TradingView Direct company coverage

REG - Hutchmed China Ltd - HUTCHMED Announces NMPA Approval for ORPATHYS

HUTCHMED (China) Limited announced that the China National Medical Products Administration (NMPA) has granted conditional approval for ORPATHYS® (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET ampl

Tone
Positive 94/100
Event
Regulatory and legal
Published
02 Jul 2026 08:40
Source
TradingView
Stock Titan Direct company coverage

China approves HUTCHMED’s ORPATHYS for MET-driven gastric cancer

HUTCHMED (HCM) has received conditional NMPA approval in China for ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification. This approval marks the third indication for ORPATHYS in China and

Tone
Positive 72/100
Event
Regulatory and legal
Published
02 Jul 2026 08:40
Source
Stock Titan
Investing.com Canada Direct company coverage

HUTCHMED receives China approval for ORPATHYS in gastric cancer By Investing.com

HUTCHMED announced that China's National Medical Products Administration has granted conditional approval for ORPATHYS (savolitinib) to treat advanced gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification. This marks the first selective MET inhibitor a

Tone
Positive 72/100
Event
Regulatory and legal
Published
02 Jul 2026 08:40
Source
Investing.com Canada
Market source Direct company coverage

HUTCHMED to Announce 2026 Half-Year Financial Results

HUTCHMED (China) Limited will announce its interim results for the first half of 2026 on Thursday, July 30, 2026. The company will host two webcast presentations for analysts and investors, one in English and one in Chinese (Putonghua), following the results announcement. These w

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 02:10
Source
Market source
scanx.trade Direct company coverage

HUTCHMED to announce 2026 interim results on July 30

HUTCHMED (China) Limited will release its interim financial results for the first half of 2026 on July 30, 2026. The company, focused on biopharmaceutical development for cancer and immunological diseases, will host two webcasts—one in English and one in Chinese—to discuss the re

Tone
Positive 66/100
Event
Earnings
Published
30 Jun 2026 11:40
Source
scanx.trade
Stock Titan Direct company coverage

HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts

HUTCHMED (NASDAQ: HCM) has announced it will release its interim results for the first half of 2026 on Thursday, July 30, 2026. Management will host two webcasts for investors and analysts: an English webcast on July 30 and a Putonghua webcast on July 31. The company is a commerc

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 09:40
Source
Stock Titan
Stock Titan Direct company coverage

HUTCHMED to post half-year results July 30, with analyst webcasts

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) announced it will release its 2026 half-year financial results on Thursday, July 30, 2026, at 7:00 am EDT. The company will host English and Chinese webcasts with Q&A sessions for analysts and investors, accessible live and via replay on its we

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 08:40
Source
Stock Titan
TradingView Direct company coverage

REG - Hutchmed China Ltd - HUTCHMED to Announce 2026 Half-Year Results

HUTCHMED (China) Limited will announce its interim financial results for the six months ended June 30, 2026, on Thursday, July 30, 2026. The company will host two webcast presentations for analysts and investors to discuss these results, with an English webcast on July 30 and a C

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 08:40
Source
TradingView
Stock Titan Direct company coverage

HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return

HUTCHMED (China) Limited has filed a blocklisting six-monthly return for its 2015 and 2026 Share Option Schemes, covering the period from December 29, 2025, to June 28, 2026. The report details the issuance of 7,500 ordinary shares under the 2015 scheme, with 45,768,368 shares re

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 10:39
Source
Stock Titan
TradingView Direct company coverage

REG - Hutchmed China Ltd - Announcement on blocklisting six monthly return

HUTCHMED (China) Limited has published its blocklisting six-monthly return for the period from December 29, 2025, to June 28, 2026. The report details the activity for two share option schemes, including the number of shares balance, increases, and securities issued during the pe

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 08:39
Source
TradingView
Citeline News & Insights Direct company coverage

Pivotal Phase II Results Advance HUTCHMED’s Fanregratinib Towards China Approval In ICC

HUTCHMED's fanregratinib has shown pivotal Phase II results, moving it closer to approval in China for intrahepatic cholangiocarcinoma (ICC). The article highlights the company's progress and mentions related news concerning competitors and other approvals in the field of cholang

Tone
Positive 70/100
Event
Earnings
Published
26 Jun 2026 09:46
Source
Citeline News & Insights
Moomoo Direct company coverage

Hutchmed Says Phase 2 Trial for Investigational Cancer Drug Meets Primary Endpoint

Hutchmed announced that its investigational cancer drug, sovleplenib, met its primary endpoint in a Phase 2 trial. The study focused on adult patients with primary immune thrombocytopenia (ITP) who had previously failed at least one prior therapy. This positive outcome marks a si

Tone
Positive 71/100
Event
Regulatory and legal
Published
25 Jun 2026 22:39
Source
Moomoo
Ad-hoc-news.de Direct company coverage

HUTCHMED quarterly timing, shares steady on Nasdaq

HUTCHMED (China) Ltd, an oncology-focused biotech company, is preparing to release its interim 2026 financial results in late August. While analysts hold mixed views on the stock, it trades steadily on Nasdaq, with its valuation sensitive to trial news and regulatory decisions. T

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:11
Source
Ad-hoc-news.de
grafa.com Direct company coverage

HUTCHMED reports 42.5% fanregratinib response rate

HUTCHMED announced positive Phase II data for its drug fanregratinib in patients with advanced intrahepatic cholangiocarcinoma, showing a 42.5% objective response rate in a single-arm trial conducted in China. The data supports a New Drug Application that has received priority re

Tone
Positive 74/100
Event
Market update
Published
25 Jun 2026 15:18
Source
grafa.com
The Manila Times Direct company coverage

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

HUTCHMED has released pivotal Phase II data for its drug fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (ICC) harboring FGFR2-fusions/rearrangements, which will be presented at the ESMO Gastrointestinal Cancers Congress 2026. The registration-enabling s

Tone
Positive 70/100
Event
Market update
Published
25 Jun 2026 12:40
Source
The Manila Times
London South East Direct company coverage

Hutchmed China reports positive phase two fanregratinib study data

Hutchmed China Ltd has reported positive phase two data for its drug fanregratinib, used to treat intrahepatic cholangiocarcinoma (ICC) in patients with fibroblast growth factor receptor two fusion/rearrangement. The study, conducted across 53 sites in China, met its primary endp

Tone
Positive 70/100
Event
Market update
Published
25 Jun 2026 11:25
Source
London South East
Stock Titan Direct company coverage

Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM)

HUTCHMED (NASDAQ: HCM) has reported pivotal Phase II data for its FGFR inhibitor fanregratinib in patients with advanced intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements. The study met its primary endpoint with an objective response rate of 42.5% an

Tone
Positive 72/100
Event
Market update
Published
25 Jun 2026 10:11
Source
Stock Titan
TradingView Direct company coverage

RCS - Hutchmed China Ltd - HUTCHMED Highlights Phase II Data at ESMO

HUTCHMED announced positive pivotal Phase II data for fanregratinib in intrahepatic cholangiocarcinoma (ICC) patients with FGFR2-fusions/rearrangements, to be presented at the ESMO Gastrointestinal Cancers Congress 2026. The study demonstrated a 42.5% objective response rate and

Tone
Positive 86/100
Event
Market update
Published
25 Jun 2026 06:11
Source
TradingView
AD HOC NEWS Direct company coverage

HUTCHMED analyst targets stay high, shares trade well below consensus

HUTCHMED (HCM) shares are trading significantly below analyst price targets, with the ADR closing around $10 while the consensus target remains above $20. The average analyst price target for HUTCHMED ADR is $21.07, representing over 100% upside from its current price, and the co

Tone
Positive 71/100
Event
Analyst action
Published
23 Jun 2026 18:40
Source
AD HOC NEWS